share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144：擬議出售證券
SEC announcement ·  04/16 04:29
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG高管兼董事薩瑪斯·庫爾卡尼定於2024年4月15日出售19,582股普通股，總市值約爲117萬美元。待售股票於同日通過股票期權行使收購，證券直接從發行人處獲得並以現金支付。在過去的三個月中，庫爾卡尼共出售了CRISPR Therapeutics的130,755股股票，總收益接近895萬美元。
CRISPR Therapeutics AG高管兼董事薩瑪斯·庫爾卡尼定於2024年4月15日出售19,582股普通股，總市值約爲117萬美元。待售股票於同日通過股票期權行使收購，證券直接從發行人處獲得並以現金支付。在過去的三個月中，庫爾卡尼共出售了CRISPR Therapeutics的130,755股股票，總收益接近895萬美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。